PD-1/PD-L1 inhibitors are changing the current landscape of mUC. Outcomes after discontinuation of ICI are unclear in this population.
Data from 8 European institutions was retrospectively collected. Target population was patients progressing on ICI. Univariate and multivariate analysis for overall survival (OS, calculated from the last date of ICI until death from any cause) as well as potential predictive factors of response to post-progression therapy (ppT) were performed. Tests were two-sided.
From March 2013 to April 2017, 291 patients were identified. 227 (78%) experienced progression (PD) on ICI. Median post-progression OS of ICI was 5 months (95% CI 3.7-6.3), being 8.6 (95%CI 7.5-9.7) if receiving ppT vs 1.8 (95%CI 1.5-2.1) if best supportive care alone (p
Many patients do not receive subsequent chemotherapy, including CT-naive patients. Patients who receive post-ICI therapy have good outcomes. ICI does not appear to confer resistance to CT. Retrospective analysis is prone to bias.
Clinical trial identification
Legal entity responsible for the study
Alfonso Gómez de Liaño Lista
Y. Loriot: AstraZeneca, Roche, MSD, Pfizer, Astellas, Janssen, Clovis, Bristol-Myers Squib. T. Powles: Roche/Genentech, AstraZeneca, MSD. M. Van der Heijden: Roche/Genentech, AstraZeneca, Astellas, Bristol-Myers Squib, MSD. All other authors have declared no conflicts of interest.